Susan Bobulsky Sells 5,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 5,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $19.00, for a total transaction of $95,000.00. Following the transaction, the insider directly owned 411,775 shares in the company, valued at approximately $7,823,725. The trade was a 1.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Stock Down 0.8%

Adaptive Biotechnologies stock traded down $0.14 during trading hours on Monday, hitting $17.46. 2,837,060 shares of the company traded hands, compared to its average volume of 2,101,648. The firm has a market cap of $2.79 billion, a P/E ratio of -52.91 and a beta of 2.16. The firm’s 50-day simple moving average is $14.62 and its two-hundred day simple moving average is $15.63. Adaptive Biotechnologies Corporation has a 1-year low of $9.96 and a 1-year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the period. Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $51,000. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $52,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ADPT. JPMorgan Chase & Co. lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Guggenheim reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. TD Cowen lifted their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.57.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.